36 related articles for article (PubMed ID: 27514314)
1. [Prostate cancer external beam radiotherapy].
de Crevoisier R; Pommier P; Latorzeff I; Chapet O; Chauvet B; Hennequin C
Cancer Radiother; 2016 Sep; 20 Suppl():S200-9. PubMed ID: 27516051
[TBL] [Abstract][Full Text] [Related]
2. Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".
Marvaso G; Corrao G; Repetti I; Lorubbio C; Bellerba F; Zaffaroni M; Vincini MG; Zerini D; Alessi S; Luzzago S; Mistretta FA; Fodor C; Cambria R; Cattani F; Ceci F; Musi G; De Cobelli O; Zilli T; Gandini S; Orecchia R; Petralia G; Jereczek-Fossa BA
World J Urol; 2024 Mar; 42(1):169. PubMed ID: 38492078
[TBL] [Abstract][Full Text] [Related]
3. Deep learning-based dominant index lesion segmentation for MR-guided radiation therapy of prostate cancer.
Simeth J; Jiang J; Nosov A; Wibmer A; Zelefsky M; Tyagi N; Veeraraghavan H
Med Phys; 2023 Aug; 50(8):4854-4870. PubMed ID: 36856092
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionation in prostate cancer radiotherapy: a step forward towards clinical routine.
Vischioni B; Petrucci R; Valvo F
Transl Androl Urol; 2019 Dec; 8(Suppl 5):S528-S532. PubMed ID: 32042639
[No Abstract] [Full Text] [Related]
5. MRI-guided localization of the dominant intraprostatic lesion and dose analysis of volumetric modulated arc therapy planning for prostate cancer.
Tamihardja J; Zenk M; Flentje M
Strahlenther Onkol; 2019 Feb; 195(2):145-152. PubMed ID: 30209535
[TBL] [Abstract][Full Text] [Related]
6. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in radiation oncology.
Garibaldi C; Jereczek-Fossa BA; Marvaso G; Dicuonzo S; Rojas DP; Cattani F; Starzyńska A; Ciardo D; Surgo A; Leonardi MC; Ricotti R
Ecancermedicalscience; 2017; 11():785. PubMed ID: 29225692
[TBL] [Abstract][Full Text] [Related]
8. Multimodal image registration for the identification of dominant intraprostatic lesion in high-precision radiotherapy treatments.
Ciardo D; Jereczek-Fossa BA; Petralia G; Timon G; Zerini D; Cambria R; Rondi E; Cattani F; Bazani A; Ricotti R; Garioni M; Maestri D; Marvaso G; Romanelli P; Riboldi M; Baroni G; Orecchia R
Br J Radiol; 2017 Nov; 90(1079):20170021. PubMed ID: 28830203
[TBL] [Abstract][Full Text] [Related]
9. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
[TBL] [Abstract][Full Text] [Related]
10. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
Arcangeli S; Greco C
Nat Rev Urol; 2016 Jul; 13(7):400-8. PubMed ID: 27296648
[TBL] [Abstract][Full Text] [Related]
12. The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.
Pathmanathan AU; Alexander EJ; Huddart RA; Tree AC
Future Oncol; 2016 Nov; 12(21):2495-2511. PubMed ID: 27322113
[TBL] [Abstract][Full Text] [Related]
13. Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion.
Timon G; Ciardo D; Bazani A; Garioni M; Maestri D; De Lorenzo D; Pansini F; Cambria R; Rondi E; Cattani F; Marvaso G; Zerini D; Vischioni B; Ciocca M; Russo S; Molinelli S; Golino F; Scroffi V; Rojas DP; Fodor C; Petralia G; Santoro L; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Tumori; 2016 Oct; 102(5):536-540. PubMed ID: 27514314
[TBL] [Abstract][Full Text] [Related]
14. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
Timon G; Ciardo D; Bazani A; Marvaso G; Riva G; Volpe S; Rojas DP; Renne G; Petralia G; Zerini D; Fodor C; Dicuonzo S; Maestri D; Pansini F; Cambria R; Cattani F; Golino F; Scroffi V; De Lorenzo D; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Br J Radiol; 2018 Sep; 91(1089):20160725. PubMed ID: 29750539
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
